Skip to main content

Table 2 Plasma levels of estrone, estrone sulphate and SHBG among 339 never and past users of HRT as percentage difference in hormonal measurements in relation to CYP19A1 polymorphisms

From: Alcohol-related breast cancer in postmenopausal women – effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial

Genotype

n (%)

Estrone

P-valueb

Estrone sulphate

P-valueb

SHBG

P-valueb

n = 339

∆ (95 % CI)a

∆ (95 % CI)a

∆ (95 % CI)a

rs10519297

       

AA

81 (24)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

AG

187 (55)

8 (−4;21)

0.35

10 (−1;21)

0.05

−5 (−14;6)

0.66

GG

71 (21)

1 (−13;16)

 

16 (3;31)

 

−2 (−14;11)

 

AG + GG

258 (56)

6 (−6;18)

0.34

12 (1;23)

0.03

−4 (−13;6)

0.44

rs749292

       

GG

101 (30)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

AG

169 (50)

−5 (−15;6)

0.62

−11 (−19;-2)

0.007

−3 (−12;7)

0.07

AA

69 (20)

−5 (−17;9)

 

−16 (−26;-6)

 

11 (−2;26)

 

AG + AA

238 (70)

−5 (−14;5)

0.33

−12 (−20;-4)

0.004

1 (−8;11)

0.82

rs1062033

       

CC

88 (26)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

CG

180 (53)

−2 (−13;10)

0.53

−10 (−19;-1)

0.01

−1 (−11;9)

0.45

GG

71 (21)

−7 (−20;6)

 

−16 (−26;-6)

 

6 (−7;21)

 

CG + GG

251 (74)

−4 (−14;7)

0.51

−12 (−20;-3)

0.007

1 (−9;11)

0.88

rs10046

       

AA

93 (27)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

AG

177 (52)

2 (−9;15)

0.58

4 (−5;15)

0.26

−1 (−10;10)

0.94

GG

69 (20)

−4 (−17;10)

 

11 (−2;25)

 

−2 (−14;11)

 

AG + GG

246 (73)

0 (−10;12)

0.93

6 (−3;16)

0.21

−1 (−10;9)

0.82

rs4646

       

CC

186 (55)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

CA

133 (39)

3 (−7;14)

0.68

5 (−3;15)

0.38

−4 (−13;5)

0.59

AA

20 (6)

−6 (−23;16)

 

10 (−8;31)

 

−5 (−21;15)

 

CA + AA

153 (45)

2 (−8;12)

0.73

6 (−3;15)

0.18

−4 (−13;4)

0.30

rs6493487

       

AA

203 (60)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

GA

127 (38)

−5 (−14;5)

0.27

4 (−4;14)

0.63

−5 (−13;4)

0.37

GG

9 (3)

−19 (−40;9)

 

0 (−23;29)

 

−14 (−34;13)

 

GA + GG

136 (41)

−6 (−15;4)

0.23

4 (−4;13)

0.36

−5 (−13;3)

0.22

rs2008691

       

AA

220 (65)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

GA

109 (32)

4 (−6;15)

0.35

3 (−6;12)

0.83

2 (−7;12)

0.17

GG

10 (3)

21 (−9;60)

 

0 (−21;28)

 

27 (−1;64)

 

GA + GG

119 (35)

5 (−4;16)

0.29

2 (−6;12)

0.57

4 (−5;14)

0.37

rs3751591

       

TT

241 (71)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

TC

90 (27)

2 (−9;13)

0.55

1 (−8;10)

0.50

1 (−9;11)

0.09

CC

8 (2)

19 (−13;63)

 

18 (−10;54)

 

38 (4;83)

 

CC vs. TT + TC

8 (2)

18 (−14;62)

0.29

17 (−10;53)

0.24

37 (4;82)

0.03

rs2445762

       

TT

175 (52)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

TC

142 (42)

−3 (−12;7)

0.71

−1 (−9;8)

0.71

−3 (−19;16)

0.53

CC

22 (6)

−7 (−24;13)

 

−7 (−21;10)

 

−5 (−13;4)

 

TC + CC

164 (48)

−3 (−12;6)

0.47

−2 (−10;6)

0.63

−5 (−13;4)

0.27

rs11070844

       

CC

267 (79)

0 (ref.)

 

0 (ref.)

 

0 (ref.)

 

TC

68 (20)

17 (4;31)

0.03

13 (2;25)

0.04

6 (−5;18)

0.20

TT

4 (1)

16 (−26;79)

 

23 (−16;79)

 

36 (−9;103)

 

TC + TT

72 (21)

17 (4;31)

0.009

14 (3;25)

0.01

7 (−3;19)

0.18

  1. SHBG Sex-hormone binding globulin
  2. Δ Percentage difference in hormonal measurements compared to WT
  3. aAdjusted for age, smoking (never, past, current), alcohol intake (increment of 10 g per day) and BMI (kg/m2) at baseline
  4. bP-value for trend